News coverage about NuVasive (NASDAQ:NUVA) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NuVasive earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 81 out of 100, meaning that recent press coverage is very likely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Priming the Pump: What Are Analysts Saying About NuVasive, Inc. (NASDAQ:NUVA)? – Evergreen Caller (evergreencaller.com)
- (LLY) is down at $81.60 UK Supreme Court Rules In Lilly’s Favor… (footballhebdo.com)
- The Analysts Anticipate Textron Inc (healthcaremenu.net)
- HighTower Advisors LLC Has $1.27 Million Position in Textron Inc. (TXT) (ismboard.com)
- Eli Lilly and Company Sees Unusually High Options Volume (NYSE:LLY) (campdesrecrues.com)
NuVasive (NUVA) traded up 1.57% during trading on Friday, hitting $75.86. 393,466 shares of the stock were exchanged. NuVasive has a 52 week low of $56.70 and a 52 week high of $81.06. The stock has a market capitalization of $3.84 billion, a price-to-earnings ratio of 79.60 and a beta of 1.08. The firm has a 50-day moving average of $75.80 and a 200-day moving average of $72.93.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Tuesday, April 25th. The medical device company reported $0.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.01. NuVasive had a net margin of 5.35% and a return on equity of 12.63%. The business had revenue of $249.86 million for the quarter, compared to the consensus estimate of $250.52 million. During the same period in the prior year, the company posted $0.34 earnings per share. NuVasive’s revenue was up 16.2% compared to the same quarter last year. Equities research analysts anticipate that NuVasive will post $2.01 earnings per share for the current fiscal year.
A number of equities research analysts have issued reports on the stock. TheStreet upgraded shares of NuVasive from a “c+” rating to a “b” rating in a research report on Wednesday, May 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $84.00 target price on shares of NuVasive in a research report on Friday, June 30th. Royal Bank Of Canada reiterated a “buy” rating and issued a $76.00 target price on shares of NuVasive in a research report on Monday, May 15th. BMO Capital Markets reiterated a “buy” rating and issued a $82.00 target price on shares of NuVasive in a research report on Tuesday, April 11th. Finally, Canaccord Genuity restated a “buy” rating and set a $84.00 price target (up previously from $82.00) on shares of NuVasive in a research note on Wednesday, April 26th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $80.27.
ILLEGAL ACTIVITY WARNING: This news story was posted by BBNS and is the property of of BBNS. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://baseballnewssource.com/markets/nuvasive-nuva-receiving-somewhat-positive-press-coverage-study-finds-updated-updated/1043895.html.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with our FREE daily email newsletter.